RGEN - Repligen: Management Gambled With 2020 Guidance But Long-Term Growth Story Looks Compelling
Investment Thesis
Repligen 1-year share price performance. Source: TradingView
Repligen (RGEN) is one of the few companies within the Life Sciences industry that has not withdrawn its 2020 guidance as a result of coronavirus, and the company's share price recovered rapidly since hitting late February lows of $84.5 to trade as high as $142 in mid-May.
Last week, Repligen's share price declined rapidly, falling to $120.26. Since I can find no significant underlying reasons for this decline, I consider that the current price represents a good entry point to acquire some shares in